| Identification | Back Directory | [Name]
Benzeneacetic acid, 4-[(4-hydroxy-1-naphthalenyl)methyl]-3,5-bis(trifluoromethyl)- | [CAS]
3049368-51-3 | [Synonyms]
ZTA-261
Benzeneacetic acid, 4-[(4-hydroxy-1-naphthalenyl)methyl]-3,5-bis(trifluoromethyl)- | [Molecular Formula]
C21H14F6O3 | [MOL File]
3049368-51-3.mol | [Molecular Weight]
428.33 |
| Chemical Properties | Back Directory | [Boiling point ]
473.5±40.0 °C(predicted) | [density ]
1.447±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [pka]
4.02±0.10(predicted) |
| Hazard Information | Back Directory | [Uses]
ZTA-261 is a highly selective and low toxic thyroid hormone receptor β subtype (THR-β) agonist (IC50=6.3 nM) that reduces body weight and visceral fat through a liothyronine (HY-A0070A) mediated pathway. ZTA-261 can be used in the study of lipid metabolism and obesity prevalence[1]. | [References]
[1] Nambo, et al. "Synthesis and preclinical testing of a selective beta-subtype agonist of thyroid hormone receptor ZTA-261." Communications Medicine 4.1 (2024): 152. DOI:10.1038/s43856-024-00574-z |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|